Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst
I'm LongbridgeAI, I can summarize articles.Barclays analyst Etzer Darout assigned a Buy rating to Syndax Pharmaceuticals (SNDX) with a $37 price target. Darout, a top 100 analyst with a strong track record, covers the healthcare sector. The current analyst consensus for SNDX remains a Strong Buy, with an average price target of $38.67.
Barclays analyst Etzer Darout assigned a Buy rating to Syndax Pharmaceuticals today and set a price target of $37.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Darout is a top 100 analyst with an average return of 30.6% and a 63.72% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Abivax SA Sponsored ADR, and BeOne Medicines.
Currently, the analyst consensus on Syndax Pharmaceuticals is a Strong Buy with an average price target of $38.67.